IMPACT Therapeutics, Inc. Class H (7630) Stock Statistics & Valuation Metrics

IMPACT Therapeutics, Inc. Class H has a market cap or net worth of HK$4.01B. The enterprise value is $7.65B.

IMPACT Therapeutics, Inc. Class H has 282,461,520 shares outstanding. The number of shares has decreased by -2.65% in one year.

IMPACT Therapeutics, Inc. Class H’s return on equity (ROE) is 0.30 and return on invested capital (ROIC) is -95.95%.

The current PE Ratio of IMPACT Therapeutics, Inc. Class H is ―. IMPACT Therapeutics, Inc. Class H’s PEG ratio is 2.15.

In the last 12 months, IMPACT Therapeutics, Inc. Class H had revenue of 5.33M and earned -41.23M in profits. Earnings per share was -0.15.

In the last 12 months, operating cash flow was -14.10M and capital expenditures -64.09K, giving a free cash flow of -14.16M billion.

IMPACT Therapeutics, Inc. Class H pays an annual dividend of ―, resulting in a dividend yield of ―

IMPACT Therapeutics, Inc. Class H upcoming earnings date is Aug 31, 2026, Before Open (Confirmed).

IMPACT Therapeutics, Inc. Class H as a current ratio of 3.08, with Debt / Equity ratio of 0.55%

In the past 12 months, IMPACT Therapeutics, Inc. Class H has paid 0.00 in taxes.

IMPACT Therapeutics, Inc. Class H EV to EBITDA ratio is -50.02, with an EV/FCF ratio of -115.81.

IMPACT Therapeutics, Inc. Class H has HK$156.99M in cash and marketable securities with HK$623.31K in debt, giving a net cash position of HK$156.37M billion.

Gross margin is 87.17%, with operating margin of -601.22%, and net profit margin of -773.64%.

The average price target for IMPACT Therapeutics, Inc. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―